HERVOLUTION Therapeutics Appoints Biotech Builder J. Robert Coleman as CEO to Accelerate Groundbreaking Immunotherapies to Treat Dark Genome Targets in Cancer, Aging, and Neurodegeneration
Copenhagen, Denmark & New York, USA — 19 Dec 2023— HERVOLUTION Therapeutics ApS (‘HERVOLUTION’), a pioneering biotechnology company focused on developing novel immunotherapies to treat dark genome targets in cancer, aging, and neurodegeneration, today announces the appointment of J. Robert Coleman, PhD, MBA as its Chief Executive Officer.
Robert Coleman PhD, MBA, has over 12 years’ experience in building successful biotech companies, with a particular focus on driving platform technologies from initial innovation to Phase 3 clinical trials – ultimately enabling the development of multi-asset, multi-disease area pipelines.
